Logo image of 1COV.DE

COVESTRO AG (1COV.DE) Stock Fundamental Analysis

FRA:1COV - Deutsche Boerse Ag - DE0006062144 - Common Stock - Currency: EUR

60.34  -0.14 (-0.23%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to 1COV. 1COV was compared to 67 industry peers in the Chemicals industry. 1COV has a bad profitability rating. Also its financial health evaluation is rather negative. 1COV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year 1COV has reported negative net income.
1COV had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: 1COV reported negative net income in multiple years.
In the past 5 years 1COV always reported a positive cash flow from operatings.
1COV.DE Yearly Net Income VS EBIT VS OCF VS FCF1COV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

1.2 Ratios

1COV's Return On Assets of -2.78% is on the low side compared to the rest of the industry. 1COV is outperformed by 67.16% of its industry peers.
Looking at the Return On Equity, with a value of -6.10%, 1COV is doing worse than 64.18% of the companies in the same industry.
Industry RankSector Rank
ROA -2.78%
ROE -6.1%
ROIC N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
1COV.DE Yearly ROA, ROE, ROIC1COV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

1COV's Operating Margin has declined in the last couple of years.
1COV's Gross Margin of 14.41% is on the low side compared to the rest of the industry. 1COV is outperformed by 76.12% of its industry peers.
In the last couple of years the Gross Margin of 1COV has declined.
1COV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.41%
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
1COV.DE Yearly Profit, Operating, Gross Margins1COV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

3

2. Health

2.1 Basic Checks

1COV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1COV remains at a similar level compared to 1 year ago.
1COV has more shares outstanding than it did 5 years ago.
1COV has a better debt/assets ratio than last year.
1COV.DE Yearly Shares Outstanding1COV.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
1COV.DE Yearly Total Debt VS Total Assets1COV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

An Altman-Z score of 2.22 indicates that 1COV is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.22, 1COV perfoms like the industry average, outperforming 59.70% of the companies in the same industry.
1COV has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
1COV has a Debt to Equity ratio of 0.31. This is in the better half of the industry: 1COV outperforms 67.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 2.22
ROIC/WACCN/A
WACC6.3%
1COV.DE Yearly LT Debt VS Equity VS FCF1COV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

1COV has a Current Ratio of 1.32. This is a normal value and indicates that 1COV is financially healthy and should not expect problems in meeting its short term obligations.
1COV's Current ratio of 1.32 is on the low side compared to the rest of the industry. 1COV is outperformed by 73.13% of its industry peers.
A Quick Ratio of 0.71 indicates that 1COV may have some problems paying its short term obligations.
1COV has a worse Quick ratio (0.71) than 83.58% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.71
1COV.DE Yearly Current Assets VS Current Liabilites1COV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

3

3. Growth

3.1 Past

1COV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -90.83%.
1COV shows a small growth in Revenue. In the last year, the Revenue has grown by 0.01%.
The Revenue has been growing slightly by 2.70% on average over the past years.
EPS 1Y (TTM)-90.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-347.37%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-0.94%

3.2 Future

1COV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.50% yearly.
Based on estimates for the next years, 1COV will show a small growth in Revenue. The Revenue will grow by 1.74% on average per year.
EPS Next Y122.42%
EPS Next 2Y88.03%
EPS Next 3Y60.44%
EPS Next 5Y35.5%
Revenue Next Year2.12%
Revenue Next 2Y3.66%
Revenue Next 3Y3.32%
Revenue Next 5Y1.74%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1COV.DE Yearly Revenue VS Estimates1COV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B
1COV.DE Yearly EPS VS Estimates1COV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 1COV. In the last year negative earnings were reported.
1COV is valuated quite expensively with a Price/Forward Earnings ratio of 27.67.
Based on the Price/Forward Earnings ratio, 1COV is valued a bit more expensive than the industry average as 64.18% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.34, 1COV is valued a bit cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 27.67
1COV.DE Price Earnings VS Forward Price Earnings1COV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, 1COV is valued a bit more expensive than the industry average as 61.19% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 15.29
1COV.DE Per share data1COV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as 1COV's earnings are expected to grow with 60.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y88.03%
EPS Next 3Y60.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 1COV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COVESTRO AG

FRA:1COV (7/16/2025, 2:43:26 PM)

60.34

-0.14 (-0.23%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)07-31 2025-07-31
Inst Owners41.76%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap11.40B
Analysts68.89
Price Target62.95 (4.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.01
Dividend Growth(5Y)-70.61%
DP-0.26%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-691.25%
Min EPS beat(2)-1222.75%
Max EPS beat(2)-159.74%
EPS beat(4)1
Avg EPS beat(4)-3758.66%
Min EPS beat(4)-13853.1%
Max EPS beat(4)201.01%
EPS beat(8)1
Avg EPS beat(8)-4303.1%
EPS beat(12)2
Avg EPS beat(12)-2871.29%
EPS beat(16)4
Avg EPS beat(16)-2153.19%
Revenue beat(2)0
Avg Revenue beat(2)-4.8%
Min Revenue beat(2)-5.09%
Max Revenue beat(2)-4.5%
Revenue beat(4)0
Avg Revenue beat(4)-4.72%
Min Revenue beat(4)-6.71%
Max Revenue beat(4)-2.59%
Revenue beat(8)0
Avg Revenue beat(8)-4.65%
Revenue beat(12)2
Avg Revenue beat(12)-2.45%
Revenue beat(16)5
Avg Revenue beat(16)-1.22%
PT rev (1m)0%
PT rev (3m)1.17%
EPS NQ rev (1m)0.78%
EPS NQ rev (3m)0.78%
EPS NY rev (1m)0%
EPS NY rev (3m)-54.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.67
P/S 0.81
P/FCF N/A
P/OCF 13.91
P/B 1.78
P/tB 2.18
EV/EBITDA 15.29
EPS(TTM)-2.08
EYN/A
EPS(NY)2.18
Fwd EY3.61%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)4.34
OCFY7.19%
SpS74.85
BVpS33.9
TBVpS27.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.78%
ROE -6.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.41%
FCFM N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)6.03%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
F-Score3
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA 2.09
Cap/Depr 84.99%
Cap/Sales 6.04%
Interest Coverage N/A
Cash Conversion 87.7%
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 0.71
Altman-Z 2.22
F-Score3
WACC6.3%
ROIC/WACCN/A
Cap/Depr(3y)75.52%
Cap/Depr(5y)82.02%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-347.37%
EPS Next Y122.42%
EPS Next 2Y88.03%
EPS Next 3Y60.44%
EPS Next 5Y35.5%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-0.94%
Revenue Next Year2.12%
Revenue Next 2Y3.66%
Revenue Next 3Y3.32%
Revenue Next 5Y1.74%
EBIT growth 1Y-134.13%
EBIT growth 3Y-79.32%
EBIT growth 5Y-52.83%
EBIT Next Year364.32%
EBIT Next 3Y92.23%
EBIT Next 5Y53%
FCF growth 1Y-94.44%
FCF growth 3Y-60.36%
FCF growth 5Y-28.37%
OCF growth 1Y3.27%
OCF growth 3Y-26.52%
OCF growth 5Y-8.84%